Smart delivery rather than brute force
Traditional chemotherapy hits fast-dividing cells everywhere. Peptides open a more targeted option, because many of them are exquisitely good at binding one specific receptor. If a tumour has far more of that receptor than healthy tissue, a peptide can act like a key looking for the right lock.
Idea 1 Peptide plus radiation
In peptide receptor radionuclide therapy (PRRT), a peptide that binds a receptor common on certain neuroendocrine tumours is attached to a radioactive atom. The peptide carries the radiation to the tumour cells and spares much of the surrounding tissue. A therapy of this kind, based on a somatostatin-like peptide, has been approved for certain neuroendocrine tumours, and the same principle is used for imaging.
Idea 2 Peptide plus drug
Researchers also link peptides to chemotherapy drugs, forming peptide-drug conjugates. The goal is a higher dose where it matters and a lower dose elsewhere. Several candidates are in clinical trials, with mixed results so far.
Idea 3 Teaching the immune system
Cancer cells display small fragments of their own proteins, peptides, on their surface. Some of these fragments, especially those created by mutations unique to a tumour (neoantigens), look foreign to the immune system.
Peptide vaccines aim to show the immune system those fragments in a way that provokes a response. Personalised approaches sequence a patient's tumour, predict which mutated peptides are likely to be recognised, and build a vaccine from them. Early clinical trials, often combined with immune checkpoint drugs, have produced encouraging signals in some cancers, but this is still an investigational field.
What to keep in mind
- Early does not mean proven. Small trials can show an impressive response in a handful of patients and still fail in larger studies.
- Context matters. A therapy that works for one tumour type, selected by a biomarker, may do nothing in another.
- Side effects are real. Radiation, immune activation and conjugated drugs each carry their own risks.
A word of caution about online claims
Be sceptical of any product claiming a peptide "targets" or "dissolves" cancer. Real targeted therapies are made under strict manufacturing rules, selected through diagnostic tests and given by specialised teams.
The takeaway
Peptides are well suited to finding and marking cells, which makes them valuable in oncology. The genuine progress is slow, carefully tested and delivered through specialist care.